Systemic sclerosis & Raynaud's
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes
Authors' conclusion
While the presence or treatment of GORD does not influence the development or severity of ILD, aggressive GORD treatment, in particular with a combination of PPI and H2RA, is associated with improved survival in those with SSc-ILD.
Study context
- Population
- Systemic sclerosis (SSc) patients from the Australian Scleroderma Cohort Study (ASCS), including those with SSc-ILD469 with SSc-ILD
- Participants
- 1,632 patients
- Exposure
- Gastroesophageal reflux disease (GORD) and its treatment vs no GORD or no treatment in SSc
- Outcome
- Relationship between GORD and its treatment and ILD features (severity, time to ILD development) and survival
Main finding
As reported in the abstract
GORD prevalence and impact on ILD and survival
- GORD in SSc patients
- 1539/1632 (94%)
- GORD in SSc-ILD
- 450/469 (96%)
- GORD treatment associated with improved survival in ILD
- p = 0.002
- Survival benefit, HR, proton pump inhibitor (PPI) + H2RA vs PPI alone (greater with combination), p < 0.050
- HR 0.3 vs 0.5
Observational data: associations, not effects.
Original publication
The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes. Arthritis Res Ther. Published 25 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →